IE48269B1 - A process for producing gefarnate-containing solid preparations - Google Patents
A process for producing gefarnate-containing solid preparationsInfo
- Publication number
- IE48269B1 IE48269B1 IE725/79A IE72579A IE48269B1 IE 48269 B1 IE48269 B1 IE 48269B1 IE 725/79 A IE725/79 A IE 725/79A IE 72579 A IE72579 A IE 72579A IE 48269 B1 IE48269 B1 IE 48269B1
- Authority
- IE
- Ireland
- Prior art keywords
- gefarnate
- pka
- carrier
- adjusting agent
- process according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A storage stable Gefarnate-containing solid preparation in which Gefarnate is absorbed on a basic solid carrier such as magnesium silicate, metamagnesium aluminosilicate, magnesium oxide, aluminium hydroxide gel or synthetic hydrotalcite, is obtained by treating the surface of the base with a pKa adjusting agent (other than a mono- or di- saccharide or sugar alcohol) such as citric acid, sodium citrate, polyvinyl alcohol or gum arabic, to bring its surface pKa to 9.3 or less (e.g. 3-8), and then absorbing the Gefarnate onto the treated carrier.
Description
The present invention relates to a process for producing Gefarnatecontaining solid preparations of high stability.
Gefarnate is an oily liquid and is a useful medicine and, in general, Gefarnate-containing solid preparations are produced by allowing Gefarnate to be absorbed in highly oil-absorptive solids such as inorganic silicates (referred to as carrier hereinafter). However, the Gefarnate-containing solid preparations thus obtained have no satisfactory stability, for example they produce geraniol which is a decomposite of Gefarnate.
As the result of an extensive study to overcome these problems, the inventors have previously found that Gefarnate-containing solid preparations of high stability can be produced by treating a carrier, which is selected from the group consisting of antacid aluminium compounds and magnesium compounds such as metamagnesium aluminosilicate, magnesium silicate, magnesium oxide, dry aluminium hydroxide gel or the like, with one or more of monosaccharides, disaccharides and sugar alcohols in the presence of a solvent, followed by drying and then allowing Gefarnate to be absorbed in the dried carrier (see
- 2 A 8269
Japanese Patent Application No. 64218 of 1977). The inventors further have studied the problem and the producing process of the basis of this knowledge, and found that formation of decomposites such as geraniol is correlated with the pKa value of surface of the carrier used, and that said decomposition is remarkable when solids having the surface of a high pKa value, i.e. basicity, are used as a carrier.
The present invention provides a process for producing a stable Gefarnatecontaining solid preparation which comprises absorbing Gefarnate onto an oil absorptive carrier which is a solid base, the surface of the solid base having been previously adjusted to have a pKa value of 9.3 or less by treatment with a pKa adjusting agent other than a monosaccharide, disaccharide or sugar alcohol which is capable of reducing the pKa value of the surface to 9.3 or less.
The present invention is based on the use of solid bases whose surface pKa value is adjusted to 9.3 or less as carrier. The solid bases referred to herein means absorptive solids of which the surface has a relatively high pKa value. Particularly in this case, one may mention highly oil-absorptive silicates, such as magnesium silicate (pKa 9.3<), metamagnesium aluminosilicate (pKa 9.3<) and the like, and other highly oil-absorptive compounds such as magnesium oxide (pKa 9.3<), dry aluminium hydroxide gel (pKa 9.3<) and the like. As the adjusting agent, there may be used any of the acidic, neutral or weakly basic inorganic or organic substances (except for monosaccharides, disaccharides, and sugar alcohols). Particularly, organic acids such as citric acid, synthetic or natural high polymers such as polyvinyl alcohol, gum arabic and the like are effective.
Preferably, the amountof PKa adjusting agent is 15 to 25% by weight of the carrier.
- 3 4 8 2 59
In the present invention, how to treat the solid bases with the adjusting agent is not particularly limited, if the pKa value of the surface of solid bases can be reduced to 9.3 or less. However, particularly an effective method is one comprising dissolving the adjusting agent in a solvent capable of dissolving the agent and adding the solution to the solid base, followed by drying, or comprising mixing the base and the agent and treating the mixture with a solvent capable of dissolving the agent, followed by drying; or comprising wetting the base with the solvent and mixing the base with the agent, followed by drying.
θ The pKa value of solid surface of carrier is measured according to the wellknown method with cyclohexane as a solvent [The Archieves of Practical Pharmacy, Vol. 89, No. 7, 909-913 (1969)]. Also, the phrase the pKa value of solid surface carrier is 9.3 or less means that solid surface of carrier does not turn to red by dropwise addition of phenolphthalein.
The effect of various adjusting agents to reduce the decomposition of
Gefarnate was examined using metamagnesium aluminosilicate as a solid base. The results are shown in the following Table
Decomposition (%)
Adjusting agent, (% by weight based on the
Solid base solid base) pKa at solid surface
After one At pre-week's airpa rat- tight storion age at 50°C
After two weeks airtight storage at 50°C
No agent Polyethylene glycol 6000 (18) Corn Starch (30) 9.3< 9.3< 9.3< 2.6 0.2 5.0 19.0 3.3 13.0 23.1 4.4 13.0 Metamagne- Glycine (18) 6.3 0 0.3 0.5 sium Citric acid (18) 3.3> 0 0.1 0.2 25 alumino- Gum arabic (18) 4.8-6.3 0 0.1 0.2 silicate Polyvinyl alcohol (18) 4.8-6.3 0 1.0 1.5 Polyvinyl pyrrolidone (18) 4.8-6.3 0 0.2 0.3 sodium carboxymethyl cellulose 4.8-6.3 0 0.6 0.9
(18)
- 4 48269
As is apparent from the experimental results, the decomposition of Gefarnate depends upon the pKa value of carrier surface and is particularly remarkable when the pKa value exceeds 9.3.
Next, the same effect of various adjusting agents was examined using a dry aluminium hydroxide gel, magnesium oxide and synthetic hydrotalcite as a solid base. The results are shown in the following Table.
Solid base Adjusting agent, (% by weight based on the solid base) pKa at solid surface At preparation After one After two weeks' air-weeks' airtight stor-tight stor- age at 50°C age at 50°C No agent 9.3< 1.6 10.9 12.5 Dry Polyethylene 9.3< 0.8 4.8 6.2 aluminium hydroxide gel glycol 6000 (18) Sodium citrate (18) 6.7-8.3 0.2 2.0 2.9 Citric acid (18) 3.3-4.8 0.1 1.6 2.3 No agent 9.3< 0.3 3.2 3.6 Magnesium Polyethylene glycol 6000 (18) 9.3< 0.3 2.6 3.3 oxide Sodium citrate (18) 6.7-8.3 0 1.2 1.8 Gum arabic (18) 4.8-6.3 0 0.4 0.7 No agent 9.3< 1.5 7.9 8.4 Synthetic Polyethylene glycol 6000 (18) 9.3< 0.4 3.9 5.2 hydrotalcite Sodium citrate (18) 6.7-8.3 0.1 1.2 2.1 Gum arabic (18) 6.7-8.3 0 0.7 1.2
As is apparent from the experimental results, there is little or no effect to reduce the decomposition when the pKa value of carrier surface exceeds
9.3 by treatment with a basic substance such as polyethylene glycol 6000 as the adjusting agent, whereas the stability of Gefarnate is improved when citric acid or gum arabic is used as the adjusting agent.
- 5 48269
According to the method of the present invention as described above, it becomes possible to use many solid bases which have been substantially difficult to use irrespective of their high oil-absorptivity since they decompose Gefarnate, and further to produce very stable preparations.
Solid preparations of various forms such as powder, granule, tablet and hard capsule can be produced by allowing Gefarnate to be absorbed in the carriers, of which the pKa value at solid surface is adjusted to 9.3 or less. For this purpose, there may be added, if necessary, excipients, lubricants, disintegrators or binders such as magnesium stearate, talc, starch, lactose, hydroxypropyl cellulose, calcium earboxymethyl cellulose, finely crystalline cellulose and the like. These additives may be added before or after Gefarnate is absorbed in the carriers.
The Gefarnate-containing solid preparations thus obtained contain very little decomposites such as geraniol and have an excellent stability and a good release property.
The present invention will be illustrated in more detail with reference to the following Examples, but the present invention is not limited to these Examples.
EXAMPLE 1.
Formulation (per 250 mg):
Gefarnate 50 mg
Metamagnesium aluminosilicate 160 mg
Gum arabic 40 mg
Preparation:
Eighty grams of gum arabic was dissolved in 300 g of pure water at 50°C.
This aqueous gum arabic solution was added to 320 g of metamagnesium aluminosilicate and uniformly mixed. This mixture was dried at 60° for 17 hours in a tray drier. After drying was finished, 50 g of Gefarnate was added to
- 6 48269
200 g of the powder thus obtained and uniformly mixed to obtain a powder.
EXAMPLE 2.
Formulation (per 330 mg):
Gefarnate 50 mg
Dry aluminium hydroxide gel 160 mg
Sodium citrate 30 mg
Lactose 90 mg
Preparation:
480 g of dry aluminium hydroxide gel and 90 g of sodium citrate were well mixed for 10 minutes in a mixer. The mixture was further mixed for minutes with 400 ml of pure water in the mixer and dried at 60°C for 17 hours in a tray drier. After drying was finished, 570 g of the powder thus obtained was uniformly mixed with 150 g of Gefarnate and then with 270 g of lactose. The powder obtained was filled in hard capsules to obtain a hard capsule containing about 330 mg/capsule.
EXAMPLE 3.
Formulation (per 240 mg):
Gefarnate 50 mg
Magnesium silicate 160 mg
Polyvinyl alcohol 30 mg
Preparation:
Sixty grams of polyvinyl alcohol was dissolved in 300 g of pure water at 60°C, and 320 g of magnesium silicate was added thereto, followed by uniform mixing. The mixture was dried at 60°C for 17 hours in a tray drier. After drying was finished, the mixture was powdered by means of the Fitz mill equipped with a 24-mesh screen. Thereafter, to 190 g of the powder thus obtained was uniformly mixed 50 g of Gefarnate to obtain a powder preparation.
Claims (8)
1. A process for producing a stable Gefarnate-containing solid preparation which comprises absorbing Gefarnate onto an oil absorptive carrier which is a solid base, the surface of the solid base having been previously adjusted 5 to have a pKa value of 9.3 or less by treatment with a pKa adjusting agent other than a monosaccharide, disaccharide or sugar alcohol which is capable of reducing the pKa value of the surface to 9.3 or less.
2. A process according to Claim 1, wherein the solid base is magnesium silicate, metamagnesium aluminosilicate, magnesium oxide, dry aluminium 10 hydroxide gel or synthetic hydrotalcite.
3. A process according to Claim 1 or 2 wherein the pKa adjusting agent is citric acid, sodium citrate or gum arabic.
4. A process according to any one of the preceding claims wherein the pKa value at the surface of the carrier is adjusted to 3-8. 15
5. , A process according to any one of the preceding claims wherein the amount of pKa adjusting agent is 15-25% by weight of the carrier.
6. A process according to Claim 1 substantially as hereinbefore described with reference to any one of the Examples.
7. A stable Gefarnate containing solid preparation obtained by a process 20 according to any one of the preceding claims.
8. A preparation according to Claim 7 in the form of a powder, granule, tablet or hard capsule.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP53029746A JPS6026093B2 (en) | 1978-03-14 | 1978-03-14 | Method for producing gefalnate-containing solid preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
IE790725L IE790725L (en) | 1979-09-14 |
IE48269B1 true IE48269B1 (en) | 1984-11-28 |
Family
ID=12284653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE725/79A IE48269B1 (en) | 1978-03-14 | 1979-08-08 | A process for producing gefarnate-containing solid preparations |
Country Status (17)
Country | Link |
---|---|
JP (1) | JPS6026093B2 (en) |
AR (1) | AR218711A1 (en) |
BE (1) | BE874795A (en) |
CH (1) | CH637827A5 (en) |
CS (1) | CS207784B2 (en) |
ES (1) | ES8200632A1 (en) |
FR (1) | FR2419729B1 (en) |
GB (1) | GB2016271B (en) |
HK (1) | HK49283A (en) |
IE (1) | IE48269B1 (en) |
IT (1) | IT1162282B (en) |
MT (1) | MTP843B (en) |
MX (1) | MX5996E (en) |
NL (1) | NL7901917A (en) |
PH (1) | PH16903A (en) |
PT (1) | PT69341A (en) |
ZA (1) | ZA791103B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3320583A1 (en) * | 1983-06-08 | 1984-12-13 | Dr. Karl Thomae Gmbh, 7950 Biberach | NEW GALENIC PREPARATION FORMS OF ORAL ANTIDIABETICS AND METHOD FOR THE PRODUCTION THEREOF |
DE59006174D1 (en) * | 1989-04-07 | 1994-07-28 | Ciba Geigy Ag | Pesticide active ingredient concentrates and their production. |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3432593A (en) * | 1963-09-18 | 1969-03-11 | Key Pharm Inc | Delayed and sustained release type pharmaceutical preparation |
JPS5635169B2 (en) * | 1974-02-14 | 1981-08-15 | ||
SE421042B (en) * | 1976-06-29 | 1981-11-23 | Kockums Chem | WANT TO REDUCE THE QUANTITY OF BIOLOGICAL ACTIVE SUBSTANCE REQUIRED FOR SOME BIOLOGICAL EFFECT |
JPS53148519A (en) * | 1977-05-31 | 1978-12-25 | Sumitomo Chem Co Ltd | Preparation of solid medicine containing gefarnate |
-
1978
- 1978-03-14 JP JP53029746A patent/JPS6026093B2/en not_active Expired
- 1978-08-25 PH PH21668A patent/PH16903A/en unknown
-
1979
- 1979-03-09 ZA ZA791103A patent/ZA791103B/en unknown
- 1979-03-09 NL NL7901917A patent/NL7901917A/en not_active Application Discontinuation
- 1979-03-09 AR AR275761D patent/AR218711A1/en active
- 1979-03-12 ES ES478539A patent/ES8200632A1/en not_active Expired
- 1979-03-13 MT MT843A patent/MTP843B/en unknown
- 1979-03-13 GB GB7908723A patent/GB2016271B/en not_active Expired
- 1979-03-13 FR FR7906384A patent/FR2419729B1/en not_active Expired
- 1979-03-13 IT IT48332/79A patent/IT1162282B/en active
- 1979-03-13 MX MX797810U patent/MX5996E/en unknown
- 1979-03-13 PT PT69341A patent/PT69341A/en unknown
- 1979-03-13 BE BE0/193985A patent/BE874795A/en not_active IP Right Cessation
- 1979-03-13 CS CS791652A patent/CS207784B2/en unknown
- 1979-03-14 CH CH243379A patent/CH637827A5/en not_active IP Right Cessation
- 1979-08-08 IE IE725/79A patent/IE48269B1/en not_active IP Right Cessation
-
1983
- 1983-11-03 HK HK492/83A patent/HK49283A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CS207784B2 (en) | 1981-08-31 |
ZA791103B (en) | 1980-03-26 |
HK49283A (en) | 1983-11-11 |
GB2016271A (en) | 1979-09-26 |
MX5996E (en) | 1984-09-18 |
JPS6026093B2 (en) | 1985-06-21 |
CH637827A5 (en) | 1983-08-31 |
PH16903A (en) | 1984-04-10 |
JPS54122718A (en) | 1979-09-22 |
IT1162282B (en) | 1987-03-25 |
MTP843B (en) | 1980-02-11 |
NL7901917A (en) | 1979-09-18 |
AR218711A1 (en) | 1980-06-30 |
FR2419729A1 (en) | 1979-10-12 |
IE790725L (en) | 1979-09-14 |
GB2016271B (en) | 1982-09-02 |
ES478539A0 (en) | 1981-11-01 |
IT7948332A0 (en) | 1979-03-13 |
ES8200632A1 (en) | 1981-11-01 |
PT69341A (en) | 1979-04-01 |
FR2419729B1 (en) | 1988-07-08 |
BE874795A (en) | 1979-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4956386A (en) | Pharmaceutical compositions and process for their preparation | |
KR950002883B1 (en) | Process for preparing effervescent couples | |
EP0317878B1 (en) | Stabilized pharmaceutical agents, process for preparing them, and stable pharmaceutical preparations | |
CA1040532A (en) | Process for producing solid bismuth-containing pharmaceutical compositions | |
AU658171B2 (en) | Orally administerable drugs for the treatment of central dopamine deficiency conditions | |
DE3701129A1 (en) | METHOD FOR PRODUCING DISINFECTING CONTACT LENS CLEANING AGENT TABLETS | |
IE48879B1 (en) | An analgesic effervescent powder and process for its preparation | |
US4801608A (en) | Bismuth containing composition and method for the preparation thereof | |
JPH11514629A (en) | Stable thyroid hormone containing drugs | |
EP0075992B1 (en) | Bismuth containing composition and method for the preparation thereof | |
JPH0629190B2 (en) | Novel pharmaceutical composition | |
US4066787A (en) | Stabilized prostaglandin composition and the process for the preparation thereof | |
IE48269B1 (en) | A process for producing gefarnate-containing solid preparations | |
EP0159777A1 (en) | Stabilized 4-carbamoyl-imidazolium-5-olate | |
US4465838A (en) | Oxaprozin calcium salt | |
US4376117A (en) | Creatinol-O-phosphates having therapeutical action | |
US2918485A (en) | Dihydroxy aluminum salicylates | |
US5043168A (en) | Solid choline magnesium salicylate composition and method of preparing same | |
JP3547783B2 (en) | Prophylactic and therapeutic agent for gastritis and gastric / duodenal ulcer | |
US2555463A (en) | Stabilized sodium pantothenate composition | |
US4338311A (en) | Hydrophilic choline salicylate formulation | |
KR880002266B1 (en) | Composition for inhibiting tumor development | |
KR810001315B1 (en) | Process for preparing solid type of gefarnate contained | |
US3070503A (en) | Pyrilamine resin absorbate with aspirin and/or ascorbic acid | |
EA003779B1 (en) | Stable solid pharmaceutical composition based on paracetamol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Patent lapsed |